Nigel J Cairns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2326552/publications.pdf

Version: 2024-02-01

373 papers	50,406 citations	1704 104 h-index	1825 210 g-index
402 all docs	402 docs citations	402 times ranked	39083 citing authors

#	Article	IF	Citations
1	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	27.0	3,005
2	National Institute on Agingâ€“Alzheimerâ€™s Association guidelines for the neuropathologic assessment of Alzheimerâ€™s disease: a practical approach. Acta Neuropathologica, 2012, 123, 1-11.	7.7	2,002
3	National Institute on Agingâ€“Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, 1-13.	0.8	1,968
4	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
5	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
6	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
7	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
8	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	7.7	978
9	Filamentous Î±-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 1998, 251, 205-208.	2.1	941
10	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
11	Pathological TDPâ€43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology, 2007, 61, 427-434.	5.3	840
12	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
13	TREM2 Maintains Microglial Metabolic Fitness in Alzheimerâ€™s Disease. Cell, 2017, 170, 649-663.e13.	28.9	741
14	The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathologica, 2016, 131, 75-86.	7.7	708
15	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18809-18814.	7.1	616
16	TDPâ€43 A315T mutation in familial motor neuron disease. Annals of Neurology, 2008, 63, 535-538.	5.3	572
17	Tau and AÎ² imaging, CSF measures, and cognition in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 338ra66.	12.4	560
18	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.8	535

#	Article	IF	Citations
19	Lewy Bodies Contain Altered Î±-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. American Journal of Pathology, 1998, 153, 1365-1370.	3.8	484
20	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	21.4	479
21	Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4376-85.	7.1	474
22	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurology, The, 2013, 12, 957-965.	10.2	471
23	An Assessment of Oxidative Damage to Proteins, Lipids, and DNA in Brain from Patients with Alzheimer's Disease. Journal of Neurochemistry, 1997, 68, 2061-2069.	3.9	470
24	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. American Journal of Pathology, 2007, 171, 227-240.	3.8	446
25	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 2010, 6, 202.	0.8	443
26	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.8	432
27	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics, 2012, 44, 200-205.	21.4	428
28	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	27.8	425
29	TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nature Neuroscience, 2018, 21, 228-239.	14.8	404
30	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
31	YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease. Biological Psychiatry, 2010, 68, 903-912.	1.3	382
32	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
33	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
34	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	7.7	377
35	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimerâ€™s Disease. Science Translational Medicine, 2014, 6, 226ra30.	12.4	320
36	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309

#	Article	IF	Citations
37	Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Molecular Brain Research, 1995, 28, 311-318.	2.3	304
38	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
39	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.8	302
40	Sequence Identification and Characterization of Human Carnosinase and a Closely Related Non-specific Dipeptidase. Journal of Biological Chemistry, 2003, 278, 6521-6531.	3.4	295
41	TDP-43 in the Ubiquitin Pathology of Frontotemporal Dementia With VCP Gene Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 152-157.	1.7	295
42	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	12.8	283
43	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.8	266
44	Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Research, 2003, 967, 152-160.	2.2	264
45	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.8	261
46	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nature Genetics, 1999, 21, 71-72.	21.4	260
47	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
48	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between Î²-Amyloid and Tauopathy. JAMA Neurology, 2016, 73, 1070.	9.0	246
49	Amyloidâ€beta oligomerization in Alzheimer dementia versus highâ€pathology controls. Annals of Neurology, 2013, 73, 104-119.	5.3	244
50	Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia. Journal of Neurochemistry, 1999, 73, 1590-1597.	3.9	231
51	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathologica, 2015, 129, 469-491.	7.7	218
52	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.8	213
53	Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. NeuroReport, 2001, 12, 285-288.	1.2	212
54	Novel Ubiquitin Neuropathology in Frontotemporal Dementia WithValosin-Containing ProteinGene Mutations. Journal of Neuropathology and Experimental Neurology, 2006, 65, 571-581.	1.7	206

#	Article	IF	Citations
55	Variably proteaseâ€sensitive prionopathy: A new sporadic disease of the prion protein. Annals of Neurology, 2010, 68, 162-172.	5.3	203
56	The Lewy-Body Variant of Alzheimer's Disease. British Journal of Psychiatry, 1993, 162, 385-392.	2.8	200
57	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
58	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
59	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
60	Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychological Medicine, 1992, 22, 877-884.	4.5	191
61	Decrease and Structural Modifications of Phosphatidylethanolamine Plasmalogen in the Brain with Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1999, 58, 740-747.	1.7	190
62	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid Î² in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.5	188
63	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	4.2	188
64	HDDD2 is a familial frontotemporal lobar degeneration with ubiquitinâ€positive, tauâ€negative inclusions caused by a missense mutation in the signal peptide of progranulin. Annals of Neurology, 2006, 60, 314-322.	5.3	186
65	Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Molecular Brain Research, 2003, 118, 60-71.	2.3	181
66	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.8	181
67	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
68	Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2016, 12, 882-889.	0.8	180
69	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
70	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	3.1	174
71	Pathologic Accumulation of Î±-Synuclein and AÎ² in Parkinson Disease Patients With Dementia. Archives of Neurology, 2012, 69, 1326.	4.5	173
72	Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology, 2000, 48, 868-876.	5.3	171

#	Article	IF	Citations
73	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
74	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
75	The cytoskeleton in neurodegenerative diseases. Journal of Pathology, 2004, 204, 438-449.	4.5	156
76	Neuropathological Correlates of Psychotic Phenomena in Confirmed Alzheimer's Disease. British Journal of Psychiatry, 1994, 165, 53-59.	2.8	155
77	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	7.6	150
78	Two-dimensional map of human brain proteins. Electrophoresis, 1999, 20, 907-916.	2.4	147
79	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
80	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology, 2012, 79, 221-228.	1.1	144
81	Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Annals of Clinical and Translational Neurology, 2015, 2, 949-959.	3.7	144
82	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
83	Parkinsonâ€™s disease and multiple system atrophy have distinct Î±-synuclein seed characteristics. Journal of Biological Chemistry, 2019, 294, 1045-1058.	3.4	141
84	TARDBP 3â€²-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathologica, 2009, 118, 633-645.	7.7	139
85	Distinct pathological subtypes of FTLD-FUS. Acta Neuropathologica, 2011, 121, 207-218.	7.7	139
86	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	7.7	139
87	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	5.2	138
88	Amyloid imaging of Lewy bodyâ€associated disorders. Movement Disorders, 2010, 25, 2516-2523.	3.9	135
89	Visininâ€like proteinâ€1: Diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology, 2011, 70, 274-285.	5.3	132
90	Pick's disease is associated with mutations in thetau gene. Annals of Neurology, 2000, 48, 859-867.	5.3	131

#	Article	IF	Citations
91	The reduction of NADH. Life Sciences, 2001, 68, 2741-2750.	4.3	129
92	Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down Syndrome. Electrophoresis, 2001, 22, 172-179.	2.4	129
93	Diversity of Amyloid-beta Proteoforms in the Alzheimerâ€™s Disease Brain. Scientific Reports, 2017, 7, 9520.	3.3	125
94	Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease. Electrophoresis, 1999, 20, 928-934.	2.4	123
95	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	7.7	123
96	Widespread tau seeding activity at early Braak stages. Acta Neuropathologica, 2017, 133, 91-100.	7.7	122
97	Tau PET in autosomal dominant Alzheimerâ€™s disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	7.6	122
98	Genetic variants ofABCA1 modify Alzheimer disease risk and quantitative traits related to ?-amyloid metabolism. Human Mutation, 2004, 23, 358-367.	2.5	120
99	Overlap between neurodegenerative disorders. Neuropathology, 2005, 25, 111-124.	1.2	119
100	Soluble Amyloid-beta Aggregates from Human Alzheimerâ€™s Disease Brains. Scientific Reports, 2016, 6, 38187.	3.3	119
101	The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain. Brain, 1999, 122, 1709-1719.	7.6	116
102	Î±-Internexin Is Present in the Pathological Inclusions of Neuronal Intermediate Filament Inclusion Disease. American Journal of Pathology, 2004, 164, 2153-2161.	3.8	116
103	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage, 2017, 161, 171-178.	4.2	116
104	The Revised National Alzheimerâ€™s Coordinating Centerâ€™s Neuropathology Formâ€”Available Data and New Analyses. Journal of Neuropathology and Experimental Neurology, 2018, 77, 717-726.	1.7	116
105	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	9.0	112
106	Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathologica, 2015, 129, 39-52.	7.7	111
107	The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 210-219.	1.7	111
108	Haplotypes extending across ACE are associated with Alzheimer's disease. Human Molecular Genetics, 2003, 12, 859-867.	2.9	108

#	Article	IF	Citations
109	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.5	108
110	TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neuroscience Letters, 2018, 678, 8-15.	2.1	105
111	VCP Mutations Causing Frontotemporal Lobar Degeneration Disrupt Localization of TDP-43 and Induce Cell Death. Journal of Biological Chemistry, 2009, 284, 12384-12398.	3.4	104
112	Down's Syndrome: Upâ€Regulation of Î²â€Amyloid Protein Precursor and Ï„ mRNAs and Their Defective Coordination. Journal of Neurochemistry, 1994, 62, 1062-1066.	3.9	103
113	Decreased phospholipase A2 activity in Alzheimer brains. Biological Psychiatry, 1995, 37, 13-17.	1.3	100
114	Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neuroscience Letters, 1997, 230, 49-52.	2.1	97
115	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
116	Synaptophysin gene expression in schizophrenia. British Journal of Psychiatry, 2000, 176, 236-242.	2.8	96
117	Decreased brain levels of 2â€²,3â€²-cyclic nucleotide-3â€²-phosphodiesterase in Down syndrome and Alzheimerâ€™s disease. Neurobiology of Aging, 2001, 22, 547-553.	3.1	96
118	Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 139-145.	3.0	95
119	The Structural Basis for Optimal Performance of Oligothiopheneâ€Based Fluorescent Amyloid Ligands: Conformational Flexibility is Essential for Spectral Assignment of a Diversity of Protein Aggregates. Chemistry - A European Journal, 2013, 19, 10179-10192.	3.3	95
120	Î±-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. Nature Genetics, 1999, 22, 16-17.	21.4	93
121	Alteration of Caspases and Apoptosis-Related Proteins in Brains of Patients with Alzheimer's Disease. Biochemical and Biophysical Research Communications, 2001, 281, 84-93.	2.1	92
122	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. JAMA Neurology, 2013, 70, 736.	9.0	92
123	Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. Neuroscience Letters, 1995, 200, 57-60.	2.1	91
124	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
125	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathologica, 2012, 124, 373-382.	7.7	89
126	Upregulation of the Anti-apoptotic Protein Bcl-2 May Be an Early Event in Neurodegeneration: Studies on Parkinson's and Incidental Lewy Body Disease. Biochemical and Biophysical Research Communications, 1997, 240, 84-87.	2.1	88

#	Article	IF	Citations
127	Overexpressed protein disulfide isomerase in brains of patients with sporadic Creutzfeldtâ€“Jakob disease. Neuroscience Letters, 2002, 334, 196-200.	2.1	87
128	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	10.2	87
129	Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neuroscience Letters, 2001, 303, 79-82.	2.1	86
130	Specific changes of sulfatide levels in individuals with preâ€clinical Alzheimer's disease: an early event in disease pathogenesis. Journal of Neurochemistry, 2013, 127, 733-738.	3.9	84
131	Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Annals of Neurology, 2017, 81, 549-559.	5.3	83
132	Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurology, 2015, 72, 789.	9.0	82
133	Multisite assessment of NIAâ€AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 164-169.	0.8	82
134	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neuroscience Letters, 2003, 341, 177-180.	2.1	81
135	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	7.6	79
136	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	4.4	79
137	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78
138	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine, 2017, 9, .	12.4	78
139	The quantification of gene expression in an animal model of brain ischaemia using TaqManâ„¢ real-time RT-PCR. Molecular Brain Research, 2002, 106, 101-116.	2.3	77
140	Pathological Correlates of White Matter Hyperintensities on Magnetic Resonance Imaging. Dementia and Geriatric Cognitive Disorders, 2015, 39, 92-104.	1.5	77
141	[3H](-)nicotine binding sites in fetal human brain. Brain Research, 1988, 475, 1-7.	2.2	74
142	A Presenilin-1 Truncating Mutation Is Present in Two Cases with Autopsy-Confirmed Early-Onset Alzheimer Disease. American Journal of Human Genetics, 1998, 62, 70-76.	6.2	74
143	Enrichment of human brain proteins by heparin chromatography. Electrophoresis, 1999, 20, 2970-2976.	2.4	74
144	Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neuroscience Letters, 1997, 222, 183-186.	2.1	73

#	Article	IF	Citations
145	Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome. Neuroscience Letters, 1999, 260, 9-12.	2.1	71
146	Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Human Mutation, 2008, 29, 512-521.	2.5	71
147	Superoxide Dismutase SOD1, Encoded on Chromosome 21, but Not SOD2 Is Overexpressed in Brains of Patients With Down Syndrome. Journal of Investigative Medicine, 2001, 49, 41-46.	1.6	70
148	Analysis of IFT74as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurology, 2006, 6, 44.	1.8	70
149	Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies. Current Neurology and Neuroscience Reports, 2014, 14, 499.	4.2	70
150	Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neuroscience Letters, 1996, 212, 111-114.	2.1	68
151	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp>lzheimer <scp>D</scp>isease <scp>N</scp>euroimaging <scp>I</scp>nitiative (<scp>ADNI</scp>) and the <scp>D</scp>ominantly <scp>I</scp>nherited <scp>A</scp>lzheimer <scp>N</scp>etwork (<scp>DIAN</scp>). Neuropathology, 2015, 35, 390-400.	1.2	68
152	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.1	67
153	Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias. Archives of Neurology, 2007, 64, 535.	4.5	66
154	Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics - Clinical Applications, 2007, 1, 1373-1384.	1.6	66
155	Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Neuroscience Letters, 1996, 214, 33-36.	2.1	62
156	Genetic variants associated with Alzheimerâ€™s disease confer different cerebral cortex cell-type population structure. Genome Medicine, 2018, 10, 43.	8.2	62
157	A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. Stem Cell Reports, 2019, 13, 939-955.	4.8	62
158	Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain. PLoS ONE, 2012, 7, e49483.	2.5	62
159	Tumour necrosis factor-Î± gene polymorphisms and Alzheimer's disease. Neuroscience Letters, 2003, 350, 61-65.	2.1	61
160	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology, 2014, 83, 434-440.	1.1	61
161	Neuropathological Correlates of Behavioural Disturbance in Confirmed Alzheimer's Disease. British Journal of Psychiatry, 1993, 163, 364-368.	2.8	59
162	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimer's and Dementia, 2013, 9, 176-188.	0.8	58

#	Article	IF	Citations
163	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Molecular Neurodegeneration, 2019, 14, 18.	10.8	58
164	Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in lateâ€onset sporadic Alzheimer's disease. Psychiatry and Clinical Neurosciences, 2000, 54, 523-529.	1.8	56
165	Evidence against increased oxidative DNA-damage in Down syndrome. Neuroscience Letters, 1997, 235, 137-140.	2.1	55
166	The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. NeuroReport, 2001, 12, 631-634.	1.2	55
167	Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochemical and Biophysical Research Communications, 2002, 296, 970-975.	2.1	55
168	Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neuroscience Letters, 2001, 300, 41-44.	2.1	54
169	Î²-Secretase (BACE) and GSK-3 mRNA levels in Alzheimerâ€™s disease. Molecular Brain Research, 2003, 116, 155-158.	2.3	53
170	Neuropathologic Heterogeneity in HDDD1: A Familial Frontotemporal Lobar Degeneration With Ubiquitin-positive Inclusions and Progranulin Mutation. Alzheimer Disease and Associated Disorders, 2007, 21, 1-7.	1.3	53
171	TAR DNA-Binding Protein 43 Immunohistochemistry Reveals Extensive Neuritic Pathology in FTLD-U: A Midwest-Southwest Consortium for FTLD Study. Journal of Neuropathology and Experimental Neurology, 2008, 67, 271-279.	1.7	53
172	NMR spectroscopy of human post mortem cerebrospinal fluid: Distinction of Alzheimer's disease from control using pattern recognition and statistics. NMR in Biomedicine, 1993, 6, 163-167.	2.8	52
173	Aberrant expression of bcl-2 gene family in Down's syndrome brains. Molecular Brain Research, 1997, 48, 53-59.	2.3	52
174	In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. NeuroImage, 2017, 148, 296-304.	4.2	52
175	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
176	Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in down's syndrome and Alzheimer's Disease. Life Sciences, 1996, 59, 537-544.	4.3	50
177	?-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathologica, 2004, 108, 213-23.	7.7	50
178	What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?. Neuropathology, 2008, 28, 351-365.	1.2	50
179	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology, 2013, 80, 2121-2129.	1.1	49
180	An optimistic view for quantifying mRNA in post-mortem human brain. Molecular Brain Research, 2003, 116, 7-16.	2.3	48

#	Article	IF	Citations
181	Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. Journal of Neural Transmission, 2008, 115, 1661-1671.	2.8	48
182	Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. Journal of Neural Transmission, 2010, 117, 227-239.	2.8	48
183	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	48
184	Sequence variants of IDE are associated with the extent of Î²-amyloid deposition in the Alzheimer's disease brain. Neurobiology of Aging, 2005, 26, 795-802.	3.1	47
185	The levels of water-soluble and triton-soluble AÎ² are increased in Alzheimer's disease brain. Brain Research, 2012, 1450, 138-147.	2.2	47
186	TDP-43 expression influences amyloidÎ² plaque deposition and tau aggregation. Neurobiology of Disease, 2017, 103, 154-162.	4.4	47
187	Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. Translational Psychiatry, 2018, 8, 265.	4.8	47
188	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimer's and Dementia, 2015, 11, 815-822.	0.8	46
189	Apolipoprotein E Ïµ4 Allele Has No Effect on Age at Onset or Duration of Disease in Cases of Frontotemporal Dementia with Pick- or Microvacuolar-Type Histology. Experimental Neurology, 2000, 163, 452-456.	4.1	45
190	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.8	45
191	Differential expression of molecular chaperones in brain of patients with Down syndrome. Electrophoresis, 2001, 22, 1233-1241.	2.4	44
192	Olfactory bulb in multiple system atrophy. Movement Disorders, 2003, 18, 938-942.	3.9	44
193	Amyloid precursor protein mRNA levels in Alzheimer's disease brain. Molecular Brain Research, 2004, 122, 1-9.	2.3	43
194	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	12.8	43
195	Polyamines in frontal cortex of patients with Down syndrome and Alzheimer disease. Neuroscience Letters, 1996, 206, 193-195.	2.1	42
196	Shortfalls in the peptidyl-prolyl cisâ€“trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias. Neurobiology of Disease, 2004, 17, 237-249.	4.4	42
197	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. Journal of Biological Chemistry, 2016, 291, 27204-27218.	3.4	42
198	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	3.1	42

#	Article	IF	Citations
199	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
200	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	2.7	41
201	Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down Syndrome and Alzheimer's disease. Neuroscience Letters, 1998, 251, 45-48.	2.1	40
202	Candidate gene association studies of the Î±4 (CHRNA4) and Î²2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neuroscience Letters, 2004, 358, 142-146.	2.1	40
203	Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Human Molecular Genetics, 2008, 17, 759-767.	2.9	39
204	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
205	What does the study of the spatial patterns of pathological lesions tell us about the pathogenesis of neurodegenerative disorders?. Neuropathology, 2001, 21, 1-12.	1.2	38
206	A deep learning framework identifies dimensional representations of Alzheimerâ€™s Disease from brain structure. Nature Communications, 2021, 12, 7065.	12.8	38
207	Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 5-8.	1.7	37
208	A quantitative study of Î±-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. Journal of Neural Transmission, 2014, 121, 171-181.	2.8	37
209	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Communications, 2020, 2, fcaa025.	3.3	37
210	Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome. Neuroscience Letters, 1999, 260, 141-145.	2.1	36
211	Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology, 2013, 81, 520-527.	1.1	36
212	Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (AÎ²) in Alzheimerâ€™s Disease. Scientific Reports, 2016, 6, 35636.	3.3	36
213	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	7.6	36
214	Common variants of ACE contribute to variable age-at-onset of Alzheimerâ€™s disease. Human Genetics, 2004, 114, 478-483.	3.8	35
215	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	1.7	35
216	Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neuroscience Letters, 1997, 221, 161-164.	2.1	34

#	Article	IF	Citations
217	What does the study of the spatial patterns of pathological lesions tell us about the pathogenesis of neurodegenerative disorders?. Neuropathology, 2001, 21, 1-12.	1.2	34
218	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology, 2017, 88, 1273-1281.	1.1	34
219	Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Valâ†'Ile) mutation cases: A morphometric investigation. Journal of the Neurological Sciences, 1997, 149, 177-184.	0.6	33
220	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging, 2009, 30, 656-665.	3.1	33
221	Novel Types of Frontotemporal Lobar Degeneration: Beyond Tau and TDP-43. Journal of Molecular Neuroscience, 2011, 45, 402-408.	2.3	33
222	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	10.8	33
223	Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. Neuroscience Letters, 1997, 222, 68-69.	2.1	32
224	Evidence for Apoptosis in the Fetal Down Syndrome Brain. Journal of Child Neurology, 2001, 16, 438-442.	1.4	32
225	Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease. Neuroscience Letters, 2005, 374, 124-128.	2.1	32
226	Synthesis of Thiopheneâ€Based Optical Ligands That Selectively Detect Tau Pathology in Alzheimer's Disease. Chemistry - A European Journal, 2017, 23, 17127-17135.	3.3	32
227	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology Core. Alzheimer's and Dementia, 2010, 6, 274-279.	0.8	31
228	Î²A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the Î²A4 amyloid precursor protein gene and sporadic Alzheimer's disease. Neuroscience Letters, 1993, 149, 137-140.	2.1	30
229	Decreased transcription factor junD in brains of patients with Down syndrome. Neuroscience Letters, 1998, 252, 159-162.	2.1	30
230	Risk of incident clinical diagnosis of Alzheimer's diseaseâ€"type dementiaÂattributable to pathologyâ€confirmed vascular disease. Alzheimer's and Dementia, 2017, 13, 613-623.	0.8	30
231	Endogenous opioids in frontal cortex of patients with Down syndrome. Neuroscience Letters, 1996, 203, 111-114.	2.1	29
232	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
233	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 3825.	12.8	29
234	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	9.0	29

#	Article	IF	Citations
235	Expression of Cellular Prion Protein in the Frontal and Occipital Lobe in Alzheimer's Disease, Diffuse Lewy Body Disease, and in Normal Brain: An Immunohistochemical Study. Journal of Histochemistry and Cytochemistry, 2005, 53, 929-940.	2.5	28
236	Interaction of Neuritic Plaques and Education Predicts Dementia. Alzheimer Disease and Associated Disorders, 2008, 22, 188-193.	1.3	28
237	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1086-1092.	1.7	28
238	Neuroendocrine-Specific Protein C, a Marker of Neuronal Differentiation, Is Reduced in Brain of Patients with Down Syndrome and Alzheimer's Disease. Biochemical and Biophysical Research Communications, 2000, 276, 329-334.	2.1	27
239	Molecular Analysis of the Presenilin 1 (S182) Gene in â€œSporadicâ€•Cases of Alzheimer's Disease: Identification and Characterisation of Unusual Splice Variants. Journal of Neurochemistry, 2002, 66, 1774-1777.	3.9	27
240	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.1	27
241	In vivo [¹⁸ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2018, 90, e896-e906.	1.1	27
242	Parkinson disease clinical subtypes: key features & clinical milestones. Annals of Clinical and Translational Neurology, 2020, 7, 1272-1283.	3.7	27
243	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
244	A quantitative study of the pathological changes in white matter in multiple system atrophy. Neuropathology, 2007, 27, 221-227.	1.2	26
245	Spatial patterns of the tau pathology in progressive supranuclear palsy. Neurological Sciences, 2013, 34, 337-344.	1.9	26
246	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. Movement Disorders, 2021, 36, 948-954.	3.9	26
247	Neuronal intranuclear inclusions are ultrastructurally and immunologically distinct from cytoplasmic inclusions of neuronal intermediate filament inclusion disease. Acta Neuropathologica, 2005, 110, 360-368.	7.7	25
248	Thyroid stimulating hormone â€” Receptor overexpression in brain of patients with Down Syndrome and Alzheimer's disease. Life Sciences, 1999, 64, 1037-1044.	4.3	24
249	Spatial patterns of Î±-synuclein positive glial cytoplasmic inclusions in multiple system atrophy. Movement Disorders, 2004, 19, 109-112.	3.9	24
250	Amyloid-Î² Plaques in Clinical Alzheimerâ€™s Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity. Frontiers in Neurology, 2018, 9, 169.	2.4	24
251	Mutation analysis of patients with neuronal intermediate filament inclusion disease (NIFID). Neurobiology of Aging, 2006, 27, 778.e1-778.e6.	3.1	23
252	The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease. Acta Neuropathologica, 2011, 121, 219-228.	7.7	23

#	Article	IF	Citations
253	Staging tau pathology with tau PET in Alzheimerâ€™s disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	4.8	23
254	Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. Neuroscience Letters, 1999, 273, 61-63.	2.1	22
255	No evidence for an association between Saitohin Q7R polymorphism and Alzheimer's disease. Annals of Neurology, 2002, 52, 690-691.	5.3	22
256	Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration?. Neuropathology, 2002, 22, 133-146.	1.2	22
257	FUS Immunogold Labeling TEM Analysis of the Neuronal Cytoplasmic Inclusions of Neuronal Intermediate Filament Inclusion Disease: A Frontotemporal Lobar Degeneration with FUS Proteinopathy. Journal of Molecular Neuroscience, 2011, 45, 409-421.	2.3	22
258	Decreased cyclin dependent kinase in brain of patients with Down Syndrome. Neuroscience Letters, 1996, 216, 68-70.	2.1	21
259	Increased steady state mRNA levels of DNA-repair genes XRCC1, ERCC2 and ERCC3 in brain of patients with down syndrome. Life Sciences, 1999, 64, 1689-1699.	4.3	21
260	Evidence for the relation of herpes simplex virus type 1 to Down syndrome and Alzheimer's disease. Electrophoresis, 2001, 22, 445-448.	2.4	21
261	Quantifying regional Î± â€synuclein, amyloid Î², and tau accumulation in lewy body dementia. Annals of Clinical and Translational Neurology, 2022, 9, 106-121.	3.7	21
262	Brain vasopressin levels in Down Syndrome and Alzheimer's Disease. Brain Research, 1998, 806, 55-59.	2.2	20
263	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
264	Distinguishable effects of Presenilin-1 and APP717 mutations on amyloid plaque deposition. Neurobiology of Aging, 2001, 22, 367-376.	3.1	19
265	FUS: A new actor on the frontotemporal lobar degeneration stage. Neurology, 2010, 74, 354-356.	1.1	19
266	Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders. Journal of Neural Transmission, 2012, 119, 1551-1560.	2.8	19
267	The Utility of the National Alzheimerâ€™s Coordinating Centerâ€™s Database for the Rapid Assessment of Evolving Neuropathologic Conditions. Alzheimer Disease and Associated Disorders, 2020, 34, 105-111.	1.3	19
268	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	7.7	19
269	Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick's disease. Neuroscience Letters, 2002, 321, 169-172.	2.1	18
270	Clinically early-stage CSPÎ± mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. Acta Neuropathologica Communications, 2015, 3, 73.	5.2	17

#	Article	IF	Citations
271	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease. JAMA Neurology, 2016, 73, 1125.	9.0	17
272	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. Annals of Neurology, 2018, 84, 741-753.	5.3	17
273	Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. Neuropathology, 2001, 21, 266-271.	1.2	16
274	Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes. American Journal of Medical Genetics Part A, 2001, 105, 761-764.	2.4	16
275	Spinal cord mGlu1a receptorsPossible target for amyotrophic lateral sclerosis therapy. Pharmacology Biochemistry and Behavior, 2002, 73, 447-454.	2.9	16
276	Glyceraldehyde 3-phosphate dehydrogenase and endothelin-1 immunoreactivity is associated with cerebral white matter damage in dentatorubral-pallidoluysian atrophy. Neuropathology, 2003, 23, 36-43.	1.2	16
277	Amyotrophic lateral sclerosis and non-tau frontotemporal lobar degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 369-381.	1.8	16
278	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
279	Evidence against increased glycoxidation in patients with Alzheimer's disease. Neuroscience Letters, 1997, 232, 49-52.	2.1	14
280	Comparative quantitative study of â€˜signatureâ€™ pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders. Journal of Neural Transmission, 2015, 122, 1355-1367.	2.8	14
281	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14
282	Characterization of a Brain Permeant Fluorescent Molecule and Visualization of AÎ² Parenchymal Plaques, Using Real-Time Multiphoton Imaging in Transgenic Mice. Organic Letters, 2014, 16, 3640-3643.	4.6	13
283	Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Disease and Associated Disorders, 2017, 31, 232-238.	1.3	13
284	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
285	Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy. Journal of Neural Transmission, 2017, 124, 185-192.	2.8	12
286	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
287	Spatial pattern of prion protein deposits in patients with sporadic Creutzfeldt-Jakob disease. Neuropathology, 2001, 21, 19-24.	1.2	12
288	Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	3.3	12

#	Article	IF	Citations
289	The spatial patterns of Pick bodies, Pick cells and Alzheimer's disease pathology in Pick's disease. Neuropathology, 1999, 19, 64-70.	1.2	11
290	Aberrant accentuation of neurofibrillary degeneration in the hippocampus of Alzheimer's disease with amyloid precursor protein 717 and presenilin-1 gene mutations. Journal of the Neurological Sciences, 2005, 234, 55-65.	0.6	11
291	Size frequency distribution of the Î²-amyloid (aÎ²) deposits in dementia with Lewy bodies with associated Alzheimerâ€™s disease pathology. Neurological Sciences, 2009, 30, 471-477.	1.9	11
292	Pathology of the Superior Colliculus in Chronic Traumatic Encephalopathy. Optometry and Vision Science, 2017, 94, 33-42.	1.2	11
293	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	11.6	11
294	Spatial pattern of prion protein deposits in patients with sporadic Creutzfeldtâ€“Jakob disease. Neuropathology, 2001, 21, 19-24.	1.2	10
295	Spatial topography of the neurofibrillary tangles in cortical and subcortical regions in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2007, 13, 50-54.	2.2	10
296	Cortical degeneration in chronic traumatic encephalopathy and Alzheimerâ€™s disease neuropathologic change. Neurological Sciences, 2019, 40, 529-533.	1.9	10
297	Anteâ€•and postmortem tau in autosomal dominant and lateâ€•onset Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 2475-2480.	3.7	10
298	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
299	Increased phosphoglycerate kinase in the brains of patients with Down's syndrome but not with Alzheimer's disease. Clinical Science, 1999, 96, 279-285.	4.3	9
300	Deficient brain snRNP70K in patients with Down syndrome. Electrophoresis, 2001, 22, 43-48.	2.4	9
301	Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls. PLoS ONE, 2018, 13, e0200251.	2.5	9
302	Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument. Alzheimer Disease and Associated Disorders, 2020, 34, 112-117.	1.3	9
303	Genetic risk for Alzheimerâ€™s disease influences neuropathology via multiple biological pathways. Brain Communications, 2020, 2, fcaa167.	3.3	9
304	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	7.6	9
305	Neurons and extracellular neurofibrillary tangles in the hippocampal subdivisions in earlyâ€•onset familial Alzheimer's disease: A case study. Psychiatry and Clinical Neurosciences, 1997, 51, 227-231.	1.8	8
306	Increased phosphoglycerate kinase in the brains of patients with Downâ€™s syndrome but not with Alzheimerâ€™s disease. Clinical Science, 1999, 96, 279.	4.3	8

#	Article	IF	Citations
307	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	5.2	8
308	Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID). Journal of Neural Transmission, 2011, 118, 1651-1657.	2.8	7
309	Whippleâ€™s Disease Masquerades as Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 2015, 29, 85-89.	1.3	7
310	Pick's disease is associated with mutations in the tau gene. Annals of Neurology, 2000, 48, 859-867.	5.3	7
311	Variably Protease-sensitive Prionopathy in an Apparent Cognitively Normal 93-Year-Old. Alzheimer Disease and Associated Disorders, 2015, 29, 173-176.	1.3	6
312	A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation. Histology and Histopathology, 2011, 26, 185-90.	0.7	6
313	Spatial patterns of the pathological changes in the cerebellar cortex in sporadic Creutzfeldt-Jakob disease (sCJD). Folia Neuropathologica, 2003, 41, 183-9.	1.2	6
314	A quantitative study of the pathological changes in cortical neurons in sporadic Creutzfeldt-Jakob disease. Neuropathology, 2003, 23, 181-187.	1.2	5
315	Gigaxonin mutation analysis in patients with NIFID. Neurobiology of Aging, 2011, 32, 1528-1529.	3.1	5
316	Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease. Electrophoresis, 1999, 20, 928-934.	2.4	5
317	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
318	Neurons and neurofibrillary tangles in the hippocampal cortex in familial and sporadic Alzheimer's disease. Neuropathology, 1997, 17, 301-306.	1.2	3
319	Neuronal Intermediate Filament Inclusion Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 443-448.	1.8	3
320	Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). Neurological Sciences, 2011, 32, 653-659.	1.9	3
321	O5â€01â€06: TAU Pet Imaging with AVâ€1451 in Autosomal Dominant Alzheimer's Disease: Update from the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P378.	0.8	3
322	Neuropathological findings in a South Korean patient with Perry syndrome. , 2020, 39, 80-85.		3
323	Evidence for Apoptosis in the Fetal Down Syndrome Brain. Journal of Child Neurology, 2001, 16, 438.	1.4	3
324	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. , 2014, , 209-248.		3

#	Article	IF	Citations
325	Neuroanatomy and Neuropathology. , 2005, , 21-55.		2
326	ICâ€01â€03: Classifying TAU Pet Positivity With [18F]â€AVâ€1451 in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P2.	0.8	2
327	Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Neuroscience Letters, 1996, 214, 33-36.	2.1	2
328	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2
329	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 425.	1.7	1
330	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. Alzheimer's and Dementia, 2012, 8, P244.	0.8	1
331	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.8	1
332	O4-11-01: TDP-43 EXPRESSION IN AN APP/PS1 BACKGROUND REDUCES PLAQUE DEPOSITION AND REGULATES CALCINEURIN EXPRESSION. , 2016, 12, P360-P360.		1
333	Two-dimensional map of human brain proteins. , 0, , 327-336.		0
334	Spatial patterns of the pathological changes in the temporal lobe of patients with neuronal intermediate filament inclusion disease. Neuropathology, 2005, 25, 298-303.	1.2	0
335	Letter to The Editor. Journal of Neuropathology and Experimental Neurology, 2006, 65, 97.	1.7	0
336	TDP-43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a Midwest-Southwest Consortium for FTLD study. Journal of Neuropathology and Experimental Neurology, 2007, 66, 425.	1.7	0
337	The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Oldâ€”Reply. Archives of Neurology, 2010, 67, 899.	4.5	0
338	O2-07-01: Neuropathology of preclinical and incipient Alzheimer's dementia. , 2011, 7, S303-S303.		0
339	IC-P-138: POSTERIOR CEREBRAL ATROPHY ASSOCIATED WITH THE PSEN1 I229F MUTATION. , 2014, 10, P78-P79.		0
340	P4-146: POSTERIOR CEREBRAL ATROPHY ASSOCIATED WITH THE PSEN1 I229F MUTATION. , 2014, 10, P842-P842.		0
341	P2-108: Differentiating corticobasal degeneration and Alzheimer disease by longitudinal clinical and cognitive features. , 2015, 11, P525-P525.		0
342	P1-206: Clinical features of Alzheimer disease with and without lewy bodies. , 2015, 11, P428-P429.		0

#	Article	IF	Citations
343	O4-02-01: Age-related neuropathology helps distinguish autosomal dominant from late-onset Alzheimer disease. , 2015, 11, P269-P269.		0
344	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimerâ€™S Disease and Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P507.	0.8	0
345	P1â€116: Classifying TAU Pet Positivity with [18F]â€AVâ€1451 in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P446.	0.8	0
346	P3-089: Influence of Parkinsonâ€™s Disease Candidate Genes On Lewy Body Pathology in Autopsy-Confirmed Alzheimer's Disease Cases. , 2016, 12, P854-P854.		0
347	P3â€234: Similarities and Differences in Patterns of [F18]â€AVâ€1451 and [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P915.	0.8	0
348	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
349	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0
350	O3â€04â€03: Ageâ€Related Neuropathology Helps Distinguish Autosomal Dominant from Lateâ€Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P291.	0.8	0
351	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
352	P1â€099: Purification and Quantitative Characterization of Amyloidâ€Beta Oligomers from Alzheimer's Disease Brain Lysates. Alzheimer's and Dementia, 2016, 12, P439.	0.8	0
353	P1â€100: Amyloidâ€Beta (AÎ²) Isoforms and Ptms of Soluble AÎ² Oligomers from Human Brain. Alzheimer's and Dementia, 2016, 12, P439.	0.8	0
354	ICâ€Pâ€179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB₄₂, and Cognition in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P130.	0.8	0
355	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
356	[P3â€“263]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER's DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE. Alzheimer's and Dementia, 2017, 13, P1043.	0.8	0
357	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
358	[P2â€“436]: HIPPOCAMPAL SCLEROSIS AND COMORBIDITIES IN THE AGING BRAIN. Alzheimer's and Dementia, 2017, 13, P803.	0.8	0
359	[P4â€“057]: FUNCTIONAL CHANGES IN MEMORY ASSOCIATED WITH TDPâ€43 EXPRESSION IN AN APP/PSEN1 MOUSE MODEL. Alzheimer's and Dementia, 2017, 13, P1279.	0.8	0
360	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0

#	Article	IF	Citations
361	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
362	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
363	[S3â€“01â€“02]: NEUROPATHOLOGIC HETEROGENEITY IN FAMILIAL AND LATEâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P877.	0.8	0
364	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
365	ICâ€Pâ€195: QUANTIFICATION OF WHITE MATTER CELLULARITY IN PRECLINICAL AND EARLY SYMPTOMATIC ALZHEIMER DISEASE USING NEUROâ€IMMNUE IMAGING. Alzheimer's and Dementia, 2018, 14, P161.	0.8	0
366	ICâ€Pâ€062: EVALUATING NEUROâ€IMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTEM HUMAN BRAIN. Alzheimer's and Dementia, 2018, 14, P57.	0.8	0
367	ICâ€02â€01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.8	0
368	ICâ€Pâ€046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.8	0
369	Tauopathy in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041683.	0.8	0
370	Hippocampal neurobiology and function in an aged mouse model of TDP-43 proteinopathy in an APP/PSEN1 background. Neuroscience Letters, 2021, 758, 136010.	2.1	0
371	TDPâ€43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. FASEB Journal, 2007, 21, A25.	0.5	0
372	An alternative in vitro model of neurodegeneration in FTLDâ€U with PGRN mutation. FASEB Journal, 2008, 22, 58.7.	0.5	0
373	Unravelling the mysteries of frontotemporal dementia. Missouri Medicine, 2013, 110, 411-6.	0.3	0